Lonafarnib

Active substance
Lonafarnib
Domain
Metabolism and Endocrinology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Metabolic diseases
Extended indication
Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies.

1. Product

Proprietary name
Sarasar
Manufacturer
Eiger Bio
Mechanism of action
Virus inhibitor
Route of administration
Oral
Therapeutical formulation
Capsule
Budgetting framework
Extramural (GVS)

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Accelerated assessment
Submission date
April 2020
Expected Registration
December 2020
Orphan drug
Yes
Registration phase
Registration application pending

3. Therapeutic value

Therapeutic value
No judgement
Duration of treatment
Not found
References
NCT02579044

4. Expected patient volume per year

There is currently nothing known about the expected patient volume.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.